This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 422131
Submitted by lobbyist on: August 7, 2014 01:04:38 PM
Accepted by Registrar on: August 12, 2014 08:54:25 AM
Designated Filer Information
| Keon, James J |
| 4120 Yonge Street Suite 409 | |
|
Toronto, ON, M2P 2B8
|
416-223-2333 |
| Canada |
Organization Information
| Canadian Generic Pharmaceutical Association (CGPA) |
| The CGPA's mission is to promote an environment which supports and enhances the provision of affordable generic medications to Canadians and patients around the world. The Association researches and develops positions regarding a wide variety of policies, regulations and legislation that affects our member companies. We promote our sector's interests by publishing material as well as directly contacting government officials, the media and other opinion leaders and decision makers. |
| 4120 Yonge Street Suite 409 | |
|
Toronto, ON, M2P 2B8
|
416-223-2333 |
| Canada |
Relevant Affiliates
Government or Government Agency Funding
Other Controlling or Directing Interests
Active Registration Period
| August 7, 2014 | |
| February 3, 2015 |
Organization's In-House Lobbyists
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Introduction, modification or repeal of legislation, a bill or regulation
Development of a policy framework for addressing and reimbursing subsequent entry biologics. Discussion of potential expansion of Reference Drug Program. Development of policy concerning use of brand drug coupon cards. Implementation of the pan-Canadian pricing agreement for generic drugs. Addressing delays in listing certain generic drugs due to requirement of a Ministerial Order and discussion of alternatives. Development of a policy to address companies that cannot meet supply commitments for generic drugs. Discussion of listing process for generic drugs.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | August 7, 2014 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Introduction, modification or repeal of legislation, a bill or regulation
Development of a policy framework for addressing and reimbursing subsequent entry biologics. Discussion of potential expansion of Reference Drug Program. Development of policy concerning use of brand drug coupon cards. Implementation of the pan-Canadian pricing agreement for generic drugs. Addressing delays in listing certain generic drugs due to requirement of a Ministerial Order and discussion of alternatives. Development of a policy to address companies that cannot meet supply commitments for generic drugs. Discussion of listing process for generic drugs.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | August 7, 2014 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Introduction, modification or repeal of legislation, a bill or regulation
Development of a policy framework for addressing and reimbursing subsequent entry biologics. Discussion of potential expansion of Reference Drug Program. Development of policy concerning use of brand drug coupon cards. Implementation of the pan-Canadian pricing agreement for generic drugs. Addressing delays in listing certain generic drugs due to requirement of a Ministerial Order and discussion of alternatives. Development of a policy to address companies that cannot meet supply commitments for generic drugs. Discussion of listing process for generic drugs.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | February 17, 2015 |